Educational overview · Approx. 4 min read · illustrative, not advice
Cold traffic and warm traffic need different pages, not the same page shouted louder. And in this category the claims you cannot make shape the funnel as much as the ones you can.
Match the asset to the temperature
The failure mode in this category is sending cold traffic to an application form. Someone who has never heard of you, has been marketed at by every telehealth brand on the internet, and is carrying a decade of failed attempts is not going to fill in a qualification form because your headline was bold.
Cold traffic needs a briefing: an editorial asset that teaches something true and earns the right to the next step. Warm traffic, someone who read the briefing, attended the session, or came from a referral, is the audience for an application. The document you are reading is itself the pattern applied to a different audience.
Between those sits the middle: retargeting, email sequences, a second asset that goes deeper. Most operators build the top and the bottom and skip the middle, then conclude the channel does not work.
Where members actually come from
Four sources, in roughly descending order of reliability for a new business. Existing relationships, if you already operate a practice, which is the fastest and cheapest and is the reason page two treats existing practices as an advantage. Local presence and referral, including other practitioners who see the population but do not offer a program. Paid acquisition, which is the most scalable and the most expensive to learn on. And organic content, which is the slowest to start and the cheapest to sustain.
A ninety-day path realistically leans on the first two, while the third is being instrumented and the fourth is being seeded. Any plan that has paid acquisition carrying the business in month one is a plan that has never run paid acquisition.
The enrollment conversation
Cash-pay programs are sold in a conversation, not on a page. That conversation has a shape: understand the person's history and what has already failed, be explicit about what the program is and is not, be explicit about cost, be explicit about what is required of them, and be willing to decline people who are not a fit.
Declining is not a sales technique. In a program with a clinical component the clinical entity decides eligibility on clinical grounds, full stop, and the business side must never treat a clinical decline as a sales objection to be handled. Building your acquisition process so that the clinical gate is real, and is respected, is both the compliance position and, as page eleven argues, the retention position.
Our library piece on high-ticket enrollment in functional medicine covers the mechanics of the conversation itself in more depth than fits here.
What you cannot say
This category has an enforcement record and it is recent. In September 2025 FDA issued more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide over statements it deemed false or misleading. Marketing claims are where regulators reach businesses that are otherwise structured correctly.
Practical constraints: make no efficacy claims about any medication or supplement, make no guarantees of results, do not present a compounded product as equivalent to an approved drug, do not imply clinical outcomes your program has not measured, and keep clinical claims inside the clinical entity's voice where they belong.
Social proof is legitimate and powerful, but only if it is real and consented. Where this document would carry a testimonial, it carries instead. To fill that slot you need a named, consenting person describing their genuine experience, with any required disclosure, and with documentation on file. A composite, an actor, or an invented name is a fabricated endorsement, and it is the cheapest possible way to convert a marketing problem into a legal one.
Instrumentation, not vibes
From day one you want four numbers defined once and reported consistently: cost per lead, lead to consultation, consultation to enrollment, and enrollment to activation. Every seam failure on page eight shows up as a broken number in that chain.
We deliberately publish no benchmark figures for those metrics. Any benchmark we quoted would function as an implied earnings claim, and we do not have substantiated data to offer. Measure your own, weekly, and compare them to your own prior weeks rather than to numbers someone put in a deck.
Ask Atlas to put this in writing: which acquisition assets, ad accounts and funnel components are delivered in an Atlas build versus configured by the partner, itemised
- US FDA — In September 2025 FDA issued more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide over statements it deemed false or misleading. (source) [VERIFIED]
- Atlas Metabolic editorial policy — Atlas publishes no acquisition or conversion benchmarks because any such figure would function as an implied earnings claim without substantiation, and uses in place of any social proof that is not real, named and consented. [VERIFIED]